Search research articles
Contact Us
Filters
Showing results (11-20 of 26) with videos related to
Page
of 3
Sort By:
Contemporary Clinical Trials
|
April 24, 2012
Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework
A Doussau, B Asselain, M C Le Deley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 21, 2007
Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study
A Rafii, B Deval, J-F Geay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature
M Marous, I Bièche, X Paoletti, et al.
European Journal of Cancer Care
|
October 14, 2016
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study
A Brédart, S Bodson, C Le Tourneau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
E Raymond, M Campone, R Stupp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer
C Dittrich, B Coudert, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2008
Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials
S Collette, F Bonnetain, X Paoletti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
A Doussau, R Thiébaut, B Geoerger, et al.
ESMO Open
|
August 5, 2023
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
P du Rusquec, R Guimbaud, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E Saâda-Bouzid, C Defaucheux, A Karabajakian, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 26) with videos related to
Sort By:
Page
of 3
Contemporary Clinical Trials
|
April 24, 2012
Dose-finding designs in pediatric phase I clinical trials: comparison by simulations in a realistic timeline framework
A Doussau, B Asselain, M C Le Deley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
March 21, 2007
Treatment of FIGO stage IV ovarian carcinoma: results of primary surgery or interval surgery after neoadjuvant chemotherapy: a retrospective study
A Rafii, B Deval, J-F Geay, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 16, 2015
Designs of preoperative biomarkers trials in oncology: a systematic review of the literature
M Marous, I Bièche, X Paoletti, et al.
European Journal of Cancer Care
|
October 14, 2016
Patients' perceived tolerance of side effects in phase I cancer clinical trials: A qualitative study
A Brédart, S Bodson, C Le Tourneau, et al.
European Journal of Cancer (Oxford, England : 1990)
|
July 2, 2002
Multicentre phase II and pharmacokinetic study of RFS2000 (9-nitro-camptothecin) administered orally 5 days a week in patients with glioblastoma multiforme
E Raymond, M Campone, R Stupp, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 5, 2003
Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer
C Dittrich, B Coudert, L Paz-Ares, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 28, 2008
Prognosis of advanced hepatocellular carcinoma: comparison of three staging systems in two French clinical trials
S Collette, F Bonnetain, X Paoletti, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2014
A new approach to integrate toxicity grade and repeated treatment cycles in the analysis and reporting of phase I dose-finding trials
A Doussau, R Thiébaut, B Geoerger, et al.
ESMO Open
|
August 5, 2023
Evaluation of the relevance of the growth modulation index (GMI) from the FFCD 0307 randomized phase III trial comparing the sequence of two chemotherapeutic regimens
P du Rusquec, R Guimbaud, K Le Malicot, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 19, 2017
Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma
E Saâda-Bouzid, C Defaucheux, A Karabajakian, et al.
Page
of 3